YOUR HEALTH: Helping make life easier for Down patients

Painful skin conditions, loss of hair, discolored skin are challenges for Down Syndrome patients

DENVER — Researchers are going beyond skin deep to help relieve some of these painful conditions people with Down Syndrome may experience.

Down Syndrome is a birth condition where a child is born with an extra chromosome.  

It can cause both mental and physical challenges, as well as autoimmune disorders that cause painful skin lesions, patchy bald spots and loss of skin color.

The latest treatment is being used on Sam Levin.

When he was 13 years old, Sam was losing his hair.

“Kids were teasing him about it,” said his father Brian.

Doctors tried medications and injections.  It didn’t work.

Sam has a condition called alopecia areata where his immune system attacked his hair follicles. 

Sam Levin is an Ambassador for Global Down Syndrome Foundation.

A team at the Linda Crnic Institute for Down Syndrome has found which part of the immune system is hyperactive and responsible for several painful skin conditions associated with Down Syndrome.

“It’s called the interferon response, it’s the aspect of the immune system that we use to fight off viruses, but we use it only when there is a virus,” explained Dr. Joachuin Espinosa, executive director of the Crnic Institute.

“Whereas people with Down Syndrome activate the interferon response constantly.”

It causes the immune system to attack healthy cells. 

Dr. Espinoza is leading a nationwide clinical trial on tofacitinib, a JAK inhibitor already FDA approved to treat rheumatoid and psoriatic arthritis.

Participants take the pill daily for four months. 

Tofacitinib is being evaluated as an effective treatment for active skin conditions such as alopecia areata, vitiligo, hidradenitis suppurativa, psoriasis, or topic dermatitis.

The nationwide clinical trial, funded by the National Institutes for Health, was paused for three months due to COVID-19 but it is starting again and is open to Down Syndrome patients nationwide.  

It didn’t take long for Sam and his dad to become believers.

“And it is a life changer,” said Sam.

“He has a full head of hair again, not that he needed more confidence, but now he certainly has it.”

The drug is an immune suppressant, so doctors must closely monitor an increased risk for infections. 

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens at jim.mertens@wqad.com or Marjorie Bekaert Thomas at mthomas@ivanhoe.com.

Source link

Hidradenitis Suppurativa Treatment Market Size, Trends, Analysis, Demand, Outlook and Forecast to 2025

Hidradenitis Suppurativa Treatment Market Size, Trends, Analysis, Demand, Outlook and Forecast to 2025

Hidradenitis Suppurativa Treatment Market size 2020-2025 report, added by Market Study Report, unveils the current & future growth trends of this business sphere in addition to outlining details regarding the myriad geographies that form a part of the regional spectrum of Hidradenitis Suppurativa Treatment market. Intricate details about the supply & demand analysis, contributions by the top players, and market share growth statistics of the industry are also elucidated in the report.

.

Request a sample Report of Hidradenitis Suppurativa Treatment Market at: https://www.marketstudyreport.com/request-a-sample/2459388?utm_source=groundalerts.com&utm_medium=SK

This report also researches and evaluates the impact of Covid-19 outbreak on the Hidradenitis Suppurativa Treatment industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Hidradenitis Suppurativa Treatment market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

The latest report on the Hidradenitis Suppurativa Treatment market is an extensive assessment of this market space. The report depicts the market trends and outlines the data regarding the revenue generated by the market during the analysis period, alongside the projected growth rate.

The report methodically uncovers the Hidradenitis Suppurativa Treatment market and provides details about the industry size, renumeration forecast, sales graph, and potential growth factors over the forecast timeline. Analysis of each market segment along with the key growth indicators which will impact the growth of Hidradenitis Suppurativa Treatment market in the coming years is also discussed in the report.

Understanding the Hidradenitis Suppurativa Treatment market with respect to the regional outlook:

  • The report thoroughly analyzes the geographical landscape of the Hidradenitis Suppurativa Treatment market and includes regions like North America, Europe, Asia-Pacific, South America & Middle East and Africa.
  • Sales accumulated by the regions and their respective market share are elucidated in the report.
  • The report also discloses the revenue generated by each region alongside the growth rate attained by each geography over the analysis timeframe.

Ask for Discount on Hidradenitis Suppurativa Treatment Market Report at: https://www.marketstudyreport.com/check-for-discount/2459388?utm_source=groundalerts.com&utm_medium=SK

 

Other highlights from the report on the Hidradenitis Suppurativa Treatment market:

  • The competitive landscape of the Hidradenitis Suppurativa Treatment industry is examined in the report, inclusive of market players like
    • The major players covered in Hidradenitis Suppurativa Treatment are:
    • GlaxoSmithKline
    • Pfizer
    • Johnson & Johnson
    • AstraZeneca
    • Merck
    • Allergan
    • AbbVie

    .

  • The study outlines the product offerings of the industry leaders, and their various applications.
  • Current market position and sales generated over the forecast timeline, along with company profile with respect to each market leader is reviewed.
  • The report illustrates the pricing model followed by each contender alongside their profit margins and industry share.
  • According to the study, the product terrain of the Hidradenitis Suppurativa Treatment market is segmented into
    • Medications
    • Surgery
    • Others

    .

  • The report encompasses the industry share, sales amassed, and revenue held by each product segment during the forecast period.
  • The report assesses the application spectrum of the Hidradenitis Suppurativa Treatment market, which is categorized into

    .

  • Data pertaining to industry share registered by each application segment along with their market renumeration and total sales is documented in the report.
  • The study underlines the competition trends, concentration rate, and numerous other attributes of the business space.
  • The report also evaluates the marketing channels adopted by the various industry competitors.

 

For More Details On this Report: https://www.marketstudyreport.com/reports/global-hidradenitis-suppurativa-treatment-market-2020-by-company-regions-type-and-application-forecast-to-2025

 

Related Reports:

1. Global Plant-sourced Emulsifier Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
Read More: https://www.marketstudyreport.com/reports/global-plant-sourced-emulsifier-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

2. Global Trans Activator Of Transcription Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025
Read More: https://www.marketstudyreport.com/reports/global-trans-activator-of-transcription-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

 

 

 

 

 

 

Related Report : https://www.marketwatch.com/press-release/global-helicobacter-pylori-testing-market-expanding-at-75-cagr-to-reach-usd-7816-million-by-2025-2020-08-31

Contact Us:
Corporate Sales,
Market Study Report LLC
Phone: 1-302-273-0910
Toll Free: 1-866-764-2150
Email: [email protected]

 

Source link

Understanding the Pandemic Impact Tumor Necrosis Factor (TNF) Inhibitor Drugs Market trends?Analysis by Top Manufacturers AbbVie Inc., Amgen Inc., Johnson Johnson Services Inc., UCB S.A., Novartis International AG – StartupNG

We have recently published Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Report 2020 which includes analysis on COVID-19 Impact worldwide. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of the supply chain, falling business confidence, and increasing panic. All these details of Impact drivers-restraints-Opportunities are explained in the full version of the Report (PDF).
Note: Senior research analysts team has surveyed (Primary and Secondary Research) and published the 7th edition of the Report. We have monitored the situation worldwide for COVID-19 Impact Analysis.

Our Senior research analysts Team has surveyed the Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry and have included the following Key players:
AbbVie Inc., Amgen Inc., Johnson Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Merck co. Inc.

Some of the prime factors taken into consideration are various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis, and key market players of the Tumor Necrosis Factor (TNF) Inhibitor Drugs market.
[email protected] or call us on +1-312-376-8303.

Download Report from: https://www.cognitivemarketresearch.com/medical-devices–consumables/tumor-necrosis-factor-%28tnf%29-inhibitor-drugs-market-report

How to download your free copy:
[email protected]
Call us on +1-312-376-8303.
Download The report Copy from the webstie: https://www.cognitivemarketresearch.com/medical-devices–consumables/tumor-necrosis-factor-%28tnf%29-inhibitor-drugs-market-report#download_report

Scope of the Report

Market segment by types can be split into:
Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars

Market segment by the application and End users can be split into:
Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others


Following are the various regions covered by the Organic Foundry Binder market research report:

North America (U.S., Canada and Mexico)
Europe (Germany, UK , France, Italy, Russia, Spain and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia and Rest of APAC)
South America (Brazil, Argentina, Columbia and Rest of Latin America)
Middle East & Africa (Saudi Arabia, South Africa, Turkey, Nigeria, UAE and Rest of MEA)

DOWNLOAD FREE SAMPLE [email protected]: https://www.cognitivemarketresearch.com/medical-devices–consumables/tumor-necrosis-factor-%28tnf%29-inhibitor-drugs-market-report#download_report

As the government of different regions has already announced total lockdown and temporarily shutdown of industries, the overall production process is adversely affected; thus, hinder the overall Tumor Necrosis Factor (TNF) Inhibitor Drugs globally.
This report on ‘Tumor Necrosis Factor (TNF) Inhibitor Drugs’ provides an analysis of the impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of COVID-19 situation.

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market report provides an in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenarios for making the right decision.
The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of the last three years. Moreover, the report also offers a 360º outlook of the market through the competitive landscape of the global industry player and helps the companies to garner Tumor Necrosis Factor (TNF) Inhibitor Drugs Market revenue by understanding the strategic growth approaches.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here—>
Download Sample Report of Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Report 2020 (Coronavirus Impact Analysis on Tumor Necrosis Factor (TNF) Inhibitor Drugs Market)

The report provides industry analysis, important insights, and a competitive and useful advantage to the pursuers.
The report analyzes different segments and offers the current and prospects of each segment. Furthermore, this research report contains an in-depth analysis of the top players with data such as product specification, company profiles, and product picture, sales area, and base of manufacturing in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market.
The impact on the supply and demand of the raw materials, due to the COVID-19 is also analyzed in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market.

Additionally, the report consists of the product life cycle, which discusses the current stage of a product. Further, it adds manufacturing cost analysis as well as the complete manufacturing process involved. The report also adds supply chain analysis to ensure complete data of the market.

Access Exclusive Free Sample Report (COVID-19 Impact Analysis Updated Edition): Click Here—>
Download Sample Report of Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Report 2020 (Pandemic Impact Analysis Updated Edition 2020)

Following chapters are covered in Tumor Necrosis Factor (TNF) Inhibitor Drugs Market:
*************COVID Impact Analysis Edition *************
• Chapter 1 Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Overview
• Chapter 2 COVID 19 Impact
• Chapter 3 Tumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Types (Product News)
• Chapter 4 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Segment by Application
• Chapter 5 COVID Impact Analysis for Tumor Necrosis Factor (TNF) Inhibitor Drugs
• Chapter 6 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by Regions (2015-2027)
• Chapter 7 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Competition by Manufacturers
• Chapter 8 Company (Top Players) Profiles and Key Data
• Chapter 9 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Regions (2015-2020)
• Chapter 10 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Revenue by Types
• Chapter 11 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Analysis by Application
• Chapter 12 North America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Development Status and Outlook
• Chapter 13 Europe Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Development Status and Outlook
• Chapter 14 Asia Pacific Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Development Status and Outlook
• Chapter 15 South America Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Development Status and Outlook
• Chapter 16 Middle East & Africa Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Development Status and Outlook
• Chapter 17 Tumor Necrosis Factor (TNF) Inhibitor Drugs Manufacturing Cost Analysis
• Chapter 18 Marketing Strategy Analysis, Distributors/ Traders
• Chapter 19 Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Forecast (2020-2027)
• Chapter 20 Research Findings and Conclusion
Download the TOC and free sample of Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Report 2020 @ https://www.cognitivemarketresearch.com/medical-devices–consumables/tumor-necrosis-factor-%28tnf%29-inhibitor-drugs-market-report#table_of_contents.

Objectives of Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Report:
• COVID Impact Analysis on the worldwide market
• To justifiably share in-depth info regarding the decisive elements impacting the increase of industry (growth capacity, chances, drivers and industry-specific challenge and risks)
• To know the Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by pinpointing its many sub-segments
• To profile the important players and analyze their growth plans
• To endeavor the amount and value of the Tumor Necrosis Factor (TNF) Inhibitor Drugs Market sub-markets, depending on key regions (various vital states)
• To analyze the Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market concerning growth trends, prospects and also their participation in the entire sector
• To inspect and study the Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2027
• Primary worldwide Tumor Necrosis Factor (TNF) Inhibitor Drugs Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming years
• To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market.

How to download your Free Sample Copy (PDF):
[email protected]
Call us on +1-312-376-8303.
Download The report Copy from the webstie: https://www.cognitivemarketresearch.com/medical-devices–consumables/tumor-necrosis-factor-%28tnf%29-inhibitor-drugs-market-report

Source link

The Hidradenitis Suppurativa Treatment market to project Exorbitant Growth between 2019 and 2029 – Owned

Hidradenitis suppurativa treatment also called as acne inversa, is a long term dermatological disease which occur due to swollen lumps. They are painful and break open, and release fluid or pus. The most affected areas of the body are underarms, under the breasts, and groin. Additionally, disease generally occurs due to secondary infection, obstruction of hair follicles, and inflammation of certain sweat glands which are boosting the market growth of Hidradenitis suppurativa treatment. Furthermore, this can also cause cellulitis which is a dermatological infection that can spread in bloodstream leading occurrence sepsis that is influencing the growth of hidradenitis suppurativa treatment market. This medical condition is most common absorbed between 20-40 years of age. Prevalence of hidradenitis suppurative is seen three times more in females than in males. Moreover, rise in population and the changes in lifestyle of individual towards smoking and obesity causing rise of dermatological diseases are some of the factors that are positively influencing the Hidradenitis suppurativa treatment market growth during the forecast period.

Major factors driving the Hidradenitis suppurativa treatment market growth are rise in clinical trials coupled with evolving treatment options, rise prevailing cases of various dermatological affected disorders, and rise investment in research and development activities. Additionally, technological advanced treatments such as laser surgeries are boosting the Hidradenitis suppurativa treatment market growth in near future. Furthermore, FDA approvals for drug delivery and clinical trials are propelling the Hidradenitis suppurativa treatment market growth. Moreover, rise in association of Hidradenitis suppurativa with inflammatory bowel disease, cardiovascular risk factors, and metabolic syndrome are also some of the factors that are influencing the Hidradenitis suppurativa treatment market growth. However, due to low approval chances of phase II drugs, high cost of therapy, chance of side effects, development of drug reagents to many agents used in treatment, delay in process of  treatment  completion which might be due to unawareness of disease to physicians are the factors hampering the Hidradenitis suppurativa treatment market growth in near future.

To remain ‘ahead’ of your competitors, request for a sample [email protected]

https://www.persistencemarketresearch.com/samples/31202

The global Hidradenitis suppurativa treatment market is classified on the basis of clinical stages, medications, Route of administration, end users, distribution channel and region.

Based on clinical stage, Hidradenitis suppurativa treatment market is segmented as:

  • Hurley Stage 1- low,
  • Hurley Stage 2-moderate
  • Hurley Stage 3-high

Based on treatment, Hidradenitis suppurativa treatment market is segmented as:

  • Medication
    • Biologics
    • Antibiotics
    • Hormonal therapy
    • Immune suppurativa drugs
    • Zinc supplements
    • Pain medications
  • Surgery
  • Others

Based on Route of administration, Hidradenitis suppurativa treatment market is segmented as:

Based on end users, Hidradenitis suppurativa treatment market is segmented as:

  • hospitals
  • home centers
  • others

Based on distribution channels, Hidradenitis suppurativa treatment market is segmented as:

  • hospital pharmacy
  • online pharmacy
  • retail pharmacy
  • others

The global market for Hidradenitis suppurativa treatment is anticipated to experience a steady growth during the forecast period. Owing to the increase in prevalence of dermatological diseases associated with various other chronic diseases creates a more lucrative opportunity for manufactures present in the Hidradenitis suppurativa treatment market. Furthermore, increase in new product launches, technological advancement in treatment, clinical trials and others are propelling the market Hidradenitis suppurativa treatment growth over the years.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/31202

Hidradenitis suppurativa treatment Market: Regional Wise Outlook

Geographically, the hidradenitis suppurativa treatment market is segmented into North America, Europe, Latin America, South Asia, East Asia, Oceania, Middle East and Africa. North America is dominating the Hidradenitis suppurativa treatment market owing to rise in rise in dermatological infections, increase in clinical practices, clinically trained professionals. Asia Pacific is second largest contributor in the Hidradenitis suppurativa treatment market due to rise in inflammatory skin disease, healthcare awareness, and government support. However, Middle East and Africa are expected to experience lucrative market growth of Hidradenitis suppurativa treatment due to lack of availability skilled professionals, lack of technological penetration of healthcare treatments and others.

Some of the key players of the hidradenitis suppurativa treatment market are: Pfizer Inc., GlaxoSmithKline plc. AstraZeneca, Johnson & Johnson, AbbVie Inc.,  Merck & Co., Inc., TARGET Pharma Solutions, Inc.,  and Novartis AG.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/31202

Explore Extensive Coverage of PMR`s 

Life Sciences & Transformational Health Landscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]
Website – https://www.persistencemarketresearch.com

Source link

Latest News 2020: Tumor Necrosis Factor (TNF) Inhibitor Drugs Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis | Top Players: AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., etc.

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Industry Research Report Provides Detailed Insight Covering all Important Parameters Including Development Trends, Challenges, Opportunities, Key Insights and Competitive Analysis of Tumor Necrosis Factor (TNF) Inhibitor Drugs Market.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market in terms of both revenue and volume.

Get Exclusive Sample Report on Tumor Necrosis Factor (TNF) Inhibitor Drugs Market is available at https://inforgrowth.com/sample-request/6545543/tumor-necrosis-factor-tnf-inhibitor-drugs-market

Impact of COVID-19: Tumor Necrosis Factor (TNF) Inhibitor Drugs Market report analyses the impact of Coronavirus (COVID-19) on the Tumor Necrosis Factor (TNF) Inhibitor Drugs industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Tumor Necrosis Factor (TNF) Inhibitor Drugs market in 2020

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies.
https://inforgrowth.com/CovidImpact-Request/6545543/tumor-necrosis-factor-tnf-inhibitor-drugs-market

Top 10 leading companies in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and Tumor Necrosis Factor (TNF) Inhibitor Drugs products and services

Market Segmentation:

Top Players Listed in the Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Report are AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., UCB S.A., Novartis International AG, Pfizer, Inc., Merck & co., Inc., .

Based on type, The report split into Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars, .

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Others, .

Get Special Discount Up To 50%, 
https://inforgrowth.com/discount/6545543/tumor-necrosis-factor-tnf-inhibitor-drugs-market

Industrial Analysis of Tumor Necrosis Factor (TNF) Inhibitor Drugs Market:

Tumor

The study objectives of this report are:

  • To analyze global Tumor Necrosis Factor (TNF) Inhibitor Drugs status, future forecast, growth opportunity, key market and key players.
  • To present the Tumor Necrosis Factor (TNF) Inhibitor Drugs development in various regions like United States, Europe and China.
  • To strategically profile the key players and comprehensively analyze their development plan and strategies.
  • Tumor Necrosis Factor (TNF) Inhibitor Drugs market report helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
  • To define, describe and forecast the market by product type, market and key regions.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:
Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USA
Contact Name: Rohan S.
Email:[email protected]
Phone: +1-909-329-2808
UK: +44 (203) 743 1898

Source link

Hidradenitis Suppurativa Treatment Market 2020| Latest Research by key players -AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), GlaxoSmithKline plc. (UK), Johnson & Johnson Services – Owned

A new research study has been presented by Precision Market Reports (PMR) after a comprehensive analysis on Hidradenitis Suppurativa Treatment Market where user can get benefits from the complete market research report with all required useful information on market. Report discuss all major market aspects with expert opinion on current market status along with historic data as well. Detailed study Price, Share, Size & Growth, Latest News & Developments, Expansion Plan, Current Business Strategy, Top Companies, Sales, Revenue & Competitors Analysis, Production and Consumption, Demand & Supply, Industry and Business Study, Effect of Covid 19 (Buyers & Sellers) and Prediction 2020-2025.

Regions Covered in the Hidradenitis Suppurativa Treatment Market:

Americas:

  • Argentina • Brazil• Canada• Chile • Colombia • Mexico • Peru • USA • Others (Bolivia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Panama, Paraguay, Puerto Rico, Trinidad and Tobago, Uruguay, Venezuela)

Asia-Pacific:

  • Australia • Bangladesh • China • Hong Kong • India • Indonesia • Japan • Malaysia • New Zealand • Philippines • Singapore • South Korea • Taiwan • Thailand • Vietnam • Others (Cambodia, Macau, Mongolia, Myanmar, Nepal, Sri Lanka)

Central and Eastern Europe:

Belarus • Bulgaria • Croatia • Czechia • Hungary • Kazakhstan • Poland • Romania • Russia • Serbia • Slovakia • Slovenia • Ukraine • Others (Albania, Armenia, Azerbaijan, Bosnia and Herzegovina, Estonia, Georgia, Latvia, Lithuania, Moldova, North Macedonia)

Middle East and Africa:

Egypt • Iran • Israel • Kenya • Morocco • Nigeria • Saudi Arabia • South Africa • UAE • Others (Algeria, Angola, Ghana, Jordan, Kuwait, Lebanon, Mozambique, Oman, Qatar, Tanzania, Tunisia, Zambia)

Western Europe:

Austria • Belgium • Denmark • Finland • France • Germany • Greece • Ireland • Italy • Netherlands • Norway • Portugal • Spain • Sweden • Switzerland • Turkey • UK • Others (Andorra, Cyprus, Iceland, Luxembourg, Malta)

Covid-19 Scenario:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the corona virus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

Top Players & Competitive Analysis (Benefits) for Hidradenitis Suppurativa Treatment:

A competitive analysis is a strategy where we identify major competitors and research their products, sales, and marketing strategies. By doing this, you can create solid business strategies that improve upon your competitor’s. A competitive analysis helps you learn the ins and outs of how your competition works. It also helps you identify what they’re doing right and opportunities where you can easily one-up them by using a strategy they haven’t taken advantage of. Every brand can benefit from regular competitor analysis. By performing a competitor analysis, you’ll be able to:

  1. Identify gaps in the market
  2. Develop new products and services
  3. Uncover market trends
  4. Market and sell more effectively

As you can see, learning any of these four components will lead your brand down the path of achievement. But before you get too excited to start, we need to nail down a few important basics.Once you identify your true competition, you’ll need to determine what metrics you’ll be comparing across the board. Below, we’ll give nine specific factors to compare and tips on how to identify this competition in the first place.

Hidradenitis Suppurativa Treatment Competitors Analysis includes market shares for all the companies listed below, Competitors Analysis revenue chart, Competitive Dashboard, and the competitors’ latest strategies for overcoming the Covid 19 pandemic situation.

Get A PDF Sample of Hidradenitis Suppurativa Treatment Report: https://www.precisionmarketreports.com/download-sample/7800

Segmental Analysis:

Business segment reporting breaks out a company’s financial data by company divisions, subsidiaries, or other kinds of business segments. In an annual report, business segment reporting provides an accurate picture of a public company’s performance to its shareholders. Management uses business segment reporting to evaluate the income, expenses, assets, and liabilities of each business division to assess its general health—including profitability and potential pitfalls.

A segment is a component of a business that generates its own revenues and creates its own product, product lines, or service offerings. In general, if a unit of a business can be lifted out of the larger company and remain a self-sufficient entity, then it may be classified as a business segment.

Key Players:

AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US)

Segmentation:

Based on clinical stage, Hidradenitis suppurativa treatment market is segmented as:

  • Hurley Stage 1- low,
  • Hurley Stage 2-moderate
  • Hurley Stage 3-high

Based on treatment, Hidradenitis suppurativa treatment market is segmented as:

  • Medication
    • Biologics
    • Antibiotics
    • Hormonal therapy
    • Immune suppurativa drugs
    • Zinc supplements
    • Pain medications
  • Surgery
  • Others

Based on Route of administration, Hidradenitis suppurativa treatment market is segmented as:

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Key Takeaway:

  • Business segment reporting breaks out a public company’s financial data by company divisions, subsidiaries, or other kinds of business segments.
  • Business segment reporting offers a complete picture of a company’s operations for shareholders, upper management, and investors—which can be important for their decision-making.
  • Better understand and evaluate a company’s performance.
  • Assess its prospects for future net cash flows.
  • Understand the business as a whole.
  • Make more informed judgments about the company, and
  • Make clearer decisions about their investments.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart) @: https://www.precisionmarketreports.com/download-sample/7800

What Reports Provides:

  1. Comprehensive parent market analysis
  2. Major changes in dynamics of the market
  3. Details of market segmentation
  4. Former, current and expected study of size and price of the industry
  5. Evaluation of innovations in the niche industry
  6. Analysis of market share
  7. Major Player’s main strategies
  8. Segment emerging and regional markets
  9. Testimonials for companies to improve their market presence.
  10. That’s right. For classify and estimate tangible business factors, both Bottom-Up and Top-Down methods are analyzed.
  11. In addition, the results of the study were based on face-to-face or telephone interviews with the Industry Expert Panel.
  12. In order to validate a detailed and balanced industry analysis, panellists were approached from Leading Industries across the value chain including producers, distributors, service providers, business experts and consumers.

Table of Contents:

Chapter 1. Methodology and Scope:

  1. Report Overview
  2. Research Scope
  3. Research Objectives

Chapter 2. What is the Impact of Covid-19 Outbreak on the Market?

  1. Optimistic Scenario: COVID-19 is contained by May or June, With Normalcy Returning to Global
  2. Operations through the End of Q2.
  3. Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting into Q4.
  4. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Market
  5. Market Size in 2020, by Scenario
  6. Corporate Strategy the Manufacturers Should Be Thinking About Right Now

Chapter 3. Quarterly Competitive Assessment – 2020:

  1. By Players, Global Quarterly Market Size, 2019 VS 2020
  2. By Players, Headquarters and Area Served
  3. Date of Key Players Enter into Market
  4. Key Players Product Offered
  5. Mergers, Acquisitions and Expansion Plans

Chapter 4. Competition Landscape:

  1. Competition Dashboard
  2. Key Developments, By Major Vendors
  3. Competition Deep-dive
  4. Business Overview
  5. Product/Service Portfolio
  6. Key Financials
  7. Recent Market Developments
  8. Key Strategies

Chapter 5. Market Variables, Trends & Scope:

  1. COVID-19-Driven Market Dynamics and Factor Analysis
  2. Drivers
  3. Restraints
  4. Opportunities
  5. Challenges
  6. Pricing Model Analysis
  7. Monthly
  8. Annual licensing
  9. Global Market Analysis and Forecast, 2020 – 2025

10 Market Revenue Analysis (US$ Mn)

  1. Historic Growth Trends, 2020-2025
  2. Forecast Trends, 2020-2025

Chapter 6. Executive Summary:

  1. Market Overview
  2. Market Size 2015-2025
  3. Market Size CAGR by Region 2015 VS 2020 VS 2025
  4. Global Market Outlook
  5. Demand Side Trends
  6. Supply Side Trends
  7. Technology Roadmap
  8. Analysis and Recommendations

Any query? Enquire Here for Discount (COVID-19 Impact Analysis Updated Sample): https://www.precisionmarketreports.com/download-sample/7800

The study points out the limitations that aim to overcome the challenges to massive success for companies. Through means of this study, customers can conveniently obtain views on the Hidradenitis Suppurativa Treatment market based on the current scenario.

What is the Impact of Covid-19 Outbreak on the Hidradenitis Suppurativa Treatment? 

  • Optimistic Scenario: COVID-19 is contained by May or June, With Normalcy Returning to Global
  • Operations through the End of Q2.
  • Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting into Q4.
  • Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Hidradenitis Suppurativa Treatment.
  •  Hidradenitis Suppurativa Treatment Market Size in 2020.
  • Corporate Strategy the Manufacturers Should Be Thinking About Right Now

About Precision Market Reports (PMR):

Precision Market Reports provides quantified B2B research on 25,000 high-growth niche opportunities / threats that will impact 50 to 75 percent of global company revenues. Actively representing more than 5000 customers worldwide, including 50 percent of Fortune 500 global businesses as clients. Almost 25,000 top officials across eight industries worldwide approach Precision Market Reports for their pain points around revenue decisions.

Our reports provide a rare combination of concrete perspectives and qualitative research to help businesses attain sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile extensive, interspersed with relevant data, market studies.

Precision Business Reports provide objective insight and reliable data, helping companies of all sizes take timely decisions. We tailor creative solutions for our customers to help them address problems that are distinct from their business. Our aim is to empower our customers with holistic market intelligence, giving them a granular overview of the market in which they operate.

Contact Person:
Mr. Brian Smith
(Business Project Manager)
169, Elisenthal,
North Rhine- Westphalia,
Rhehin- Sieg- Kreis,
Windeck, Hohnrath,
Germany, DE- 51570.
Phone: +1 (845) 377-0269
Website: www.precisionmarketreports.com
Email: [email protected] / [email protected]

Source link

Global Hidradenitis Suppurativa Treatment Market Key Players, Industry Overview And Forecasts To 2026|TARGET PharmaSolutions, Inc., Eisai Co., Ltd, Abbott, ALLERGAN, AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson Services – Bulletin Line

Global hidradenitis suppurativa treatment market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. The global hidradenitis suppurativa treatment market is supposed to grow faster during the forecast period as a large number of ongoing clinical trial and introduction of new treatment options.

Get Sample Copy Of This Report @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hidradenitis-suppurativa-treatment-market

In the Hidradenitis Suppurativa Treatment marketing report; a meticulous investment analysis is given which forecasts forthcoming opportunities for the market players. This market report is the outcome of incessant efforts guided by knowledgeable forecasters, innovative analysts and brilliant researchers. They work with respect to detailed and diligent research on different markets, trends and emerging opportunities in the consecutive direction for the business needs. The Hidradenitis Suppurativa Treatment market report makes business well acquainted with insightful knowledge of the global, regional and local market statistics. Businesses can confidently use the data, statistics, research, and insights about the market covered in this report to make decisions about business strategies and to achieve maximum return on investment (ROI).

Few of the major competitors currently working in the global hidradenitis suppurativa treatment market are AbbVie Inc., Novartis AG, TARGET PharmaSolutions, Inc., Eisai Co., Ltd, Abbott, ALLERGAN, AstraZeneca, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Mylan N.V., LEO Pharma A/S, Zydus Cadila, among others.

Key Developments in the Market:

  • In June 2019, InflaRx reported the outcomes of the international SHINE phase IIb  study conducted for safety and efficacy study of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody used for the treatment of hidradenitis suppurativa (HS). Approximately more than 150 people are treated with this drug during the clinical study period
  • In March 2019, AbbVie Inc. and Eisai Co., Ltd received additional approval for Humira, an anti-TNF-α monoclonal antibody for treatment of hidradenitis suppurativa (HS) in Japan. The efficacy and safety studies of humira have shown positive results towards management of hidradenitis suppurativa. With the additional approval, Humira will be the first biological treatment for HS in japan after US and EU

Competitive Analysis:

Global hidradenitis suppurativa treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global hidradenitis suppurativa treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Drivers

  • Prevailing cases of various skin disorders will drive the growth of this market
  • Ongoing clinical trials along with introduction of new treatment options will boost the market growth
  • Growing investment in R&D activities along with technological advancement can also boost the market growth
  • Environmental changes due to global warming has increased the skin diseases and is contributing as one of the growth factor

Market Restraints

    • A weak pipeline of drugs restrains the growth of market as most of drugs are in phase II clinical trials indicating a less chance of approval
    • High cost of therapy along with chances of side-effects can also hamper the market growth
  • Development of drug resistance to many agents used for treatment of Hidradenitis suppurativa can impede the growth of this market also disturbs the market growth

Inquiry For Customize Report With Discount at :   https://www.databridgemarketresearch.com/toc/?dbmr=global-hidradenitis-suppurativa-treatment-market

Segmentation: Global Hidradenitis Suppurativa Treatment Market

By Clinical Stages

  • Hurley stage 1
  • Hurley stage 2
  • Hurley stage 3

By Treatment

  • Medication
  • Surgery
  • Others

By Route of Administration

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channels

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

By Geography

  • North America
  • South America
    • Brazil
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific
  • Middle East & Africa
    • South Africa
    • Rest of Middle East & Africa

Get Full Table Of content @   https://www.databridgemarketresearch.com/toc/?dbmr=global-hidradenitis-suppurativa-treatment-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, and Europe.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]

Source link

Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix(TM), Fueled by Growing Client Demand | State

EXTON, Pa., Aug. 27, 2020 /PRNewswire/ — Since its founding in 2015, Spherix Global Insights has been offering two key services to clients in the biopharma space, RealTime Dynamix™ and RealWorld Dynamix™. Published on a quarterly cadence in the US (semiannually for EU5/Canada), RealTime Dynamix™ has become the go-to source for tracking rapidly evolving markets including, but not limited to, atopic dermatitis, diabetic kidney disease, inflammatory bowel disease, migraine, multiple sclerosis, psoriasis, psoriatic and rheumatoid arthritis, and renal anemia (among others). With an independent viewpoint that provides continuous monitoring of key product prescribing and messaging metrics, along with new content introduced each wave to address evolving topics within each indication, clients have found this service to be a core resource for assessing their business.

RealWorld Dynamix™, the firm’s service that includes access to annual, large-scale patient chart audits, provides a deep dive into the patient journey within the core dermatology, gastroenterology, nephrology, neurology, and rheumatology market indications. While some of these audits focus exclusively on new start and switch populations, others capture a more holistic view of the total treated patient pool. The retrospective studies provide not only patient chart level detail, but physician intent with regard to therapy choices. With over 1,000 patient records (1,250 for EU5 markets) included in each study, clients have an invaluable tool for segment sizing and patient profiling, which helps them understand where and why they win and where and why they lose.

At the request of clients, Spherix introduced a new service this spring, Special Topix™: Impact of COVID-19 on Specialty Practices, which has been continuously tracking the impact of the pandemic in the US since March 2020. This ongoing service, which spans across Spherix’s five core specialties, highlights the trended impact on patient volume, use of telemedicine, practice capacity, issues with re-opening, industry engagement, and support, as well as the near-term outlook through the lens of specialty physicians. Wave 9 of this study will be released August 26th, with Wave 10 to follow in September.

Spherix also introduced Market Dynamix™, a service focusing on pipeline agents in newer and untapped indications. These reports included in this service involve large-scale surveys of physicians in clinical practice, along with interviews with key opinion leaders and practicing physicians, to assess pipeline product potential and future market projections. Therapeutic areas covered in recent publications include focal segmental glomerulosclerosis (FSGS), IgA nephropathy, and lupus/lupus nephritis. Upcoming reports include Alzheimer’s disease, alopecia areata, chronic spontaneous urticaria, eosinophilic esophagitis, hidradenitis suppurativa, metabolic acidosis, progressive forms of MS, uremic pruritus, and vitiligo.

Beginning in Q3 2020, Spherix will undertake a new venture to provide even more support to our clients as they prepare to launch new products or compete against new launches: Launch Dynamix™. This service exclusively evaluates new product launches and provides benchmarks to prior launches, with the aim of uncovering “what good looks like.” While general launch metrics will continue to be covered within the RealTime Dynamix™ series (e.g., market share and familiarity), this new series – with its blend of quantitative and qualitative methods – allows brand teams to go even deeper into areas like market access landscape, promotion, messaging, patient profiling, patient feedback, and degree of disruption. Each series includes six quarters of trending, covering the first 18 months of a product launch.

Launch Dynamix™ will start immediately and roll out new publications as key brands are approved within immunology, nephrology, and neurology markets. Reports are already underway for:

  • COSENTYX (secukinumab, Novartis) and TALTZ (ixekizumab, Eli Lilly) in non-radiographic axial spondyloarthritis
  • TREMFYA (guselkumab, Janssen) in psoriatic arthritis
  • ZEPOSIA (ozanimod, Celgene/BMS) and KESIMPTA (ofatumumab, Novartis) in MS

In 2021, Spherix plans to extend that coverage to track pending launches, including:

  • AbbVie’s RINVOQ in psoriatic arthritis and ankylosing spondylitis
  • Ardelyx’s tenapanor in hyperphosphatemia
  • Aurinia Pharmaceuticals’ voclosporin in lupus nephritis
  • FibroGen/Astellas/AstraZeneca’s roxadustat in renal anemia
  • Janssen’s ponesimod in multiple sclerosis
  • JAK inhibitors (Pfizer’s abrocitinib, Lilly’s OLUMIANT, and AbbVie’s RINVOQ) and LEO’s lebrikizumab in atopic dermatitis
  • UCB’s bimekizumab in psoriasis

“We are at a very exciting time at Spherix, experiencing tremendous growth and adding top talent to our team in order to stay ahead of it,” says Jennifer Robinson, President of Spherix. “Our passion and focus in the areas we cover has allowed us to become thought partners for our clients, not simply provisioners of syndicated reports. With Launch Dynamix™ and other innovations planned in 2021, we intend to stay true to our focus areas, going deeper to provide our clients with an even greater independent perspective at a time when informed decision making has become crucial.”

About Spherix Global Insights
Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:
Kristen Henn, Business Development Manager
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com

Source link

Latest Hidradenitis Suppurativa Market Report- Top Manufacturers, Growing Demand and Supply

The study includes analysis of the Hidradenitis Suppurativa Market, with their company profiles, recent developments, and the key market strategies. Hidradenitis Suppurativa Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Hidradenitis Suppurativa Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3591233

Top Company Profile Analysis in this Report

AbbVie Inc,

Aclaris Therapeutics Inc,

Afecta Pharmaceuticals Inc,

Alvotech ehf,

Amgen Inc,

and more..

Hidradenitis Suppurativa Market ReportHidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Hidradenitis Suppurativa Market Report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 6, 8 and 3 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope of this Report-
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

Reasons to Buy this Report-
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Get FLAT 25% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=3591233

List of Tables
Number of Products under Development for Hidradenitis Suppurativa, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hidradenitis Suppurativa – Pipeline by AbbVie Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by Aclaris Therapeutics Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by Afecta Pharmaceuticals Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by Alvotech ehf, H2 2020
Hidradenitis Suppurativa – Pipeline by Amgen Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by AstraZeneca Plc, H2 2020
Hidradenitis Suppurativa – Pipeline by ChemoCentryx Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by CSL Ltd, H2 2020
Hidradenitis Suppurativa – Pipeline by Ichnos Sciences Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by Immunwork Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by Incyte Corp, H2 2020
Hidradenitis Suppurativa – Pipeline by InflaRx NV, H2 2020
Hidradenitis Suppurativa – Pipeline by Innovation Pharmaceuticals Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by InSight Biopharmaceuticals Ltd, H2 2020
Hidradenitis Suppurativa – Pipeline by Johnson & Johnson, H2 2020
Hidradenitis Suppurativa – Pipeline by Kiniksa Pharmaceuticals Ltd, H2 2020
Hidradenitis Suppurativa – Pipeline by Kymera Therapeutics LLC, H2 2020
Hidradenitis Suppurativa – Pipeline by Menlo Therapeutics Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by NeuClone Pty Ltd, H2 2020
Hidradenitis Suppurativa – Pipeline by Novartis AG, H2 2020
Hidradenitis Suppurativa – Pipeline by Pfizer Inc, H2 2020
Hidradenitis Suppurativa – Pipeline by Pharmapraxis, H2 2020
Hidradenitis Suppurativa – Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, H2 2020
Hidradenitis Suppurativa – Pipeline by UCB SA, H2 2020
Hidradenitis Suppurativa – Dormant Projects, H2 2020
Hidradenitis Suppurativa – Discontinued Products, H2 2020

and more…

Source link

Patients Characterize Physical Symptoms of Hidradenitis Suppurativa Flares

Pain was identified by patients as the most defining flare symptom of hidradenitis suppurativa (HS), according to data from a study published in the British Journal of Dermatology.

As a comprehensive definition for flare has not yet been established and flare symptoms have not yet been quantitatively explored, researchers sought to characterize the physical symptoms of HS flares from patients’ perspectives. Data from 438 participants (93.8% women) in an anonymous survey posted on HS Facebook groups by group administrators from February through March, 2020 were analyzed. The mean age of participants was 37.6±10.7 years. Participants were asked to self-report Hurley stage, select symptoms from a list that they believed characterized HS flare, and to indicate their most defining HS flare symptom.

Pain was the most commonly reported flare symptom (98.9%), followed by drainage (91.8%), itchiness (81.1%), bleeding (78.8%), and an increased number of new lesions (66.7%). Nearly half of respondents (47.7%) reported experiencing all 5 symptoms during flares. Pain was most frequently reported as the most defining feature of flare (78.8%), followed by drainage (12.8%). There was no significant association between Hurley stage and the most defining flare symptom or likelihood of experiencing pain or itching during flares. Drainage was significantly more common during flares in Hurley III than Hurley I (P <.0002) and in II than I (P =.0004). New lesion flares were significantly more common in Hurley III than II (P =.0043) or I (P <.0002) and in II than I (P =.0005). Bleeding was significantly more common during flares in Hurley III than II (P =.0141) or I (P <.0002) and in II than I (P =.0206).

Limitations to this study include the lack of race, gender, and Hurley stage diversity. Facebook HS groups may not be representative of the general population.

The results of this study suggested that pain is the most defining symptom of HS flare and that new lesions are not the most defining flare symptom for most HS patients, despite the use of new lesion count as defining flares in clinical trials. The investigators believe that lesion count alone may not comprehensively characterize a flare, especially for Hurley I patients. Flare symptoms varied by disease severity, indicating flare severity may be a more useful outcome measure than flare frequency, they noted.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.

Reference

Fernandez JM, Thompson AM, Kirby JS, Hsiao JL, Shi VY. Characterizing physical symptoms of flare in hidradenitis suppurativa: A patient survey. [published online July 23, 2020]. Br J Dermatol. doi:10.1111/bjd.19412

Source link